Quinidine

Generic Name: Quinidine

Brand Names: Nuedexta

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₄N_₂O_₂

CAS Number: 56-54-2

Unique Ingredient Identifier: ITX08688JL

Background: Quinidine is a D-isomer of quinine present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm. It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug. Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.

Indication: Quinidine is indicated for the management and prophylactic therapy of atrial fibrillation/flutter, as well as the suppression of recurrent documented ventricular arrhythmias. It is also used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation..

Associated Conditions: Atrial Fibrillation or Flutter, Malaria caused by Plasmodium falciparum, Pseudobulbar Affect (PBA), Ventricular Arrhythmia

Clinical Trials

A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.

Phase 1

Not yet recruiting

Conditions: Healthy Participants

Interventions: Drug: balcinrenone/ dapagliflozin
Drug: quinidine

First Posted Date: 2025-05-19

Last Posted Date: 2025-05-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT06979388

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

Phase 1

Not yet recruiting

Conditions: Advanced Chronic Liver Disease
Healthy Participants

Interventions: Drug: AZD2389
Drug: Quinidine

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT06974565

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

Phase 1

Recruiting

Conditions: RSV Infection
Drug Drug Interaction (DDI)

Interventions: Drug: EDP-323
Drug: Itraconazole
Drug: carbamazepine
Drug: Quinidine
Drug: fluconazole

First Posted Date: 2025-02-26

Last Posted Date: 2025-02-26

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 48

Registration Number: NCT06847464

Locations: 🇺🇸
ICON, plc, San Antonio, Texas, United States

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Orforglipron
Drug: Midazolam
Drug: Quinidine

First Posted Date: 2024-11-26

Last Posted Date: 2025-02-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT06704763

Locations: 🇺🇸
ICON, Salt Lake City, Utah, United States

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Repotrectinib
Drug: Voriconazole
Drug: Quinidine

First Posted Date: 2024-07-10

Last Posted Date: 2025-03-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT06493409

Locations: 🇺🇸
Fortrea - Daytona Beach, Daytona Beach, Florida, United States

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: EDP-235
Drug: Carbamazepine
Drug: Itraconazole
Drug: Quinidine

First Posted Date: 2022-10-26

Last Posted Date: 2023-04-27

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 36

Registration Number: NCT05594602

Locations: 🇺🇸
ICON, plc., Lenexa, Kansas, United States

Quinidine Versus Verapamil in Short-coupled Idiopathic Ventricular Fibrillation

Phase 2

Conditions: Short-coupled Idiopathic Ventricular Fibrillation

Interventions: Drug: Quinidine
Drug: Verapamil

First Posted Date: 2022-10-25

Last Posted Date: 2023-09-13

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 24

Registration Number: NCT05593757

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Noord-Holland, Netherlands

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Imlunestrant
Drug: Omeprazole
Drug: Repaglinide
Drug: Quinidine
Drug: Rosuvastatin
Drug: Dextromethorphan
Drug: Digoxin

First Posted Date: 2022-07-06

Last Posted Date: 2022-11-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 113

Registration Number: NCT05444556

Locations: 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States